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BACKGROUND: Despite therapeutic advances, the prognosis of patients with metastatic soft tissue sarcoma (STS) remains extremely
poor. The results of a recent clinical phase II study, evaluating the protective effects of the semisynthetic flavonoid 7-mono-O-
(b-hydroxyethyl)-rutoside (monoHER) on doxorubicin-induced cardiotoxicity, suggest that monoHER enhances the antitumour
activity of doxorubicin in STSs.
METHODS: To molecularly explain this unexpected finding, we investigated the effect of monoHER on the cytotoxicity of doxorubicin,
and the potential involvement of glutathione (GSH) depletion and nuclear factor-kB (NF-kB) inactivation in the chemosensitising
effect of monoHER.
RESULTS: MonoHER potentiated the antitumour activity of doxorubicin in the human liposarcoma cell line WLS-160. Moreover, the
combination of monoHER with doxorubicin induced more apoptosis in WLS-160 cells compared with doxorubicin alone. MonoHER
did not reduce intracellular GSH levels. On the other hand, monoHER pretreatment significantly reduced doxorubicin-induced
NF-kB activation.
CONCLUSION: These results suggest that reduction of doxorubicin-induced NF-kB activation by monoHER, which sensitises cancer
cells to apoptosis, is involved in the chemosensitising effect of monoHER in human liposarcoma cells.
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Soft tissue sarcomas (STSs) comprise a rare and diverse group of
malignancies from mesenchymal origin, accounting for B1% of all
adult malignancies (Jemal et al, 2009). The only single agents that
are consistently associated with response rates of about 25% in
metastatic STS are doxorubicin and ifosfamide (Santoro et al,
1995; Keohan and Taub, 1997).
In a clinical phase II study with metastatic cancer patients
(Bruynzeel et al, 2007), evaluating the protective effects of the
semisynthetic flavonoid 7-mono-O-(b-hydroxyethyl)-rutoside
(monoHER) on doxorubicin-induced cardiotoxicity (Bast et al,
2007), we unexpectedly observed that of the four patients diag-
nosed with STS, three experienced objective remissions, whereas
the fourth had stable disease. This observed 75% response rate is
much better than the expected 25%. This prompted us to further
study the sensitising effect of monoHER on doxorubicin-induced
cytotoxicity.
MonoHER, like other flavonoids, may have an influence on the
pathways that are involved in the development of resistance against
doxorubicin (Kachadourian and Day, 2006; Sarkar and Li, 2007).
Nuclear factor-kB( N F - kB) is one of the key factors involved in the
development of chemoresistance (Karin, 2006; Sarkar and Li, 2008;
Baud and Karin, 2009). It has been reported that chemotherapeutic
agents, including doxorubicin, induce the activation of NF-kBi n
cancer cells (Chuang et al, 2002), thereby inducing survival signals
that inhibit apoptosis and promote cancer cell growth. Besides
NF-kB activation, increased glutathione (GSH) levels in cancer cells
have also been associated with multidrug resistance of many
tumours, as GSH can conjugate with the chemotherapeutic agent,
leading to drug inactivation and excretion (Estrela et al, 2006).
Therefore, to support our clinical finding, we evaluated the
effects of monoHER and doxorubicin on tumour cell growth,
apoptosis, intracellular GSH levels and NF-kB activation in human
STS cell lines.
MATERIALS AND METHODS
Cell culture and reagents
The human STS cell lines SKUT-1 (leiomyosarcoma), SKLMS-1
(leiomyosarcoma), HT-1080 (fibrosarcoma) and WLS-160 (lipo-
sarcoma) (Medical Oncology, VU University medical center,
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sAmsterdam, the Netherlands) were cultured under standard
conditions.
Novartis Consumer Health (Nyon, Switzerland) kindly provided
7-mono-O-(b-hydroxyethyl)-rutoside (monoHER). From Sigma
(St Louis, MO, USA), L-buthionine (SR)-sulphoximine (BSO) was
purchased and doxorubicin HCl (2mgml
 1) was obtained from
Pharmacia Upjohn BV (Woerden, the Netherlands). All other
chemicals were of analytical grade.
Cell growth inhibition by sulphorhodamine B assay
The human STS cell lines were either untreated or pretreated with
50mM monoHER. After 1h of incubation, medium was removed
and replaced with fresh medium containing different concentra-
tions of doxorubicin (0.001–10mM). After 72h of incubation, cell
viability was examined by the sulphorhodamine B assay (Vichai
and Kirtikara, 2006).
Caspase-3/7 assay for detecting apoptosis
WLS-160 cells were either untreated or pretreated with 50mM
monoHER for 1h, and then exposed to 10mM doxorubicin for an
additional 6h. After treatment, activation of caspase-3/7 was
quantified by the Caspase-Glo 3/7 assay kit (Promega Corporation,
Madison, WI, USA).
Measurement of intracellular GSH
WLS-160 cells were incubated with 50mM monoHER or 50mM BSO
for 1, 6 or 24h. After incubation, cells were washed with PBS,
harvested by treatment with trypsin-EDTA (Gibco, Paisley, UK)
and washed again with ice-cold PBS (Gibco). After centrifugation,
cells were resuspended in ice-cold extraction buffer (0.1% Triton
X-100 and 0.6% SSA, Sigma) and sonicated in icy water for
2–3min. The extracts were used for determination of intracellular
GSH using an enzymatic recycle method (Rahman et al, 2006).
Nuclear factor-jB measurement
WLS-160 cells were treated with 10mM doxorubicin for 1.5, 3, 6 or
24h. In another experiment, the cells were either untreated or
pretreated for 1h with 50mM monoHER before doxorubicin
exposure (10mM; 6h). Nuclear factor-kB expression was
determined in nuclear extracts of the cells (Hofmann et al, 1999)
using the TransAM NF-kB p50 transcription factor assay kit
(Active Motif, Rixensart, Belgium). Protein concentrations were
determined using the method of Bradford (Biorad, Veenendaal, the
Netherlands).
Statistical analysis
All experiments were performed, at least, in triplicate. Results are
given as mean±s.d. or as a typical example. The statistical
significance of the differences between experimental groups and
controls was determined by Student’s t-test. P-values p0.05 were
considered statistically significant.
RESULTS
As shown in Table 1, monoHER pretreatment did not significantly
influence the antitumour activity of doxorubicin in SKUT-1,
SKLMS-1 and HT-1080 cells. However, pretreatment of the
liposarcoma cell line, WLS-160, with 50mM monoHER for 1h
before doxorubicin exposure shifted the growth inhibition curve of
doxorubicin to the left (Figure 1A). MonoHER alone did not affect
tumour growth. These results indicate that monoHER potentiated
the antitumour activity of doxorubicin in WLS-160 cells.
The effect of monoHER on doxorubicin-induced apoptosis in
WLS-160 cells as assessed by caspase-3/7 activation is shown in
Figure 1B. Doxorubicin treatment (10mM; 6h) strongly induced
caspase-3/7 activity. Pretreatment of the cells with 50mM mono-
HER for 1h before doxorubicin exposure significantly enhanced
the doxorubicin-induced caspase-3/7 activation. MonoHER alone
had no effect on caspase-3/7 activity. These findings indicate that
monoHER sensitised these cancer cells to doxorubicin-induced
apoptosis.
As shown in Figure 1C, treatment of WLS-160 cells with 50mM
monoHER for 1, 6 or 24h did not affect intracellular GSH levels.
In contrast, the GSH synthesis inhibitor BSO induced a time-
dependent GSH depletion in WLS-160 cells. Moreover, BSO also
enhanced the antitumour activity of doxorubicin (data not shown).
These results indicate that intracellular GSH depletion can
sensitise WLS-160 cells to doxorubicin-induced apoptosis. How-
ever, this mechanism is not involved in the chemosensitising
effects of monoHER.
Doxorubicin treatment (10mM; 1.5, 3, 6 and 24h) significantly
induced NF-kB DNA-binding activity in WLS-160 cells compared
with untreated controls. Within the measured time range, NF-kB
activation was maximal at 6h of drug exposure (data not shown).
Figure 1D shows that pretreatment of cells with 50mM monoHER
for 1h before 6h of doxorubicin exposure significantly reduced
doxorubicin-induced activation of NF-kB. MonoHER alone had no
effect on the basal NF-kB level in WLS-160 cells. These results
suggest that reduction of doxorubicin-induced NF-kB activation
might be involved in the sensitising effect of monoHER on the
antitumour effect of doxorubicin.
DISCUSSION
In this paper, we show that monoHER can enhance the cytotoxicity
of doxorubicin, possibly via modulation of NF-kB.
Four different human STS cell lines were investigated. Only in
the liposarcoma cell line, WLS-160, pretreatment with monoHER
resulted in a significantly greater inhibition of cancer cell growth.
This different response on monoHER pretreatment between the
different cell lines is possibly because of the known large diversity
in STS and the subsequent response to chemotherapy (Van
Glabbeke et al, 1999; Verweij, 2009). The molecular mechanism
behind the observed sensitising effect of monoHER in the
responding liposarcoma cell line, WLS-160, was further explored.
First, we investigated how cytotoxicity of doxorubicin and the
chemosensitising effect of monoHER were mediated. Doxorubicin
as a single agent activated caspase-3/7 activity and thus induced
apoptosis in WLS-160 cells. Pretreatment of these cells with
monoHER resulted in a significantly greater induction of
apoptosis. These results suggest that the greater degree of cancer
cell death by the combination of monoHER with doxorubicin is
mediated by the induction of an apoptotic pathway.
As multidrug resistance of many cancer cells is associated with
increased intracellular GSH levels, GSH depletion is a potential
strategy to sensitise tumour cells to chemotherapeutics and modify
Table 1 IC50 values (mM) of growth inhibition by doxorubicin
a
Human STS
cell line Doxorubicin
Doxorubicin +
monoHER
SKLMS-1 0.063±0.009 0.066±0.007
SKUT-1 0.048±0.008 0.045±0.009
HT-1080 0.024±0.005 0.027±0.006
WLS-160 0.016±0.003 0.0075±0.001*
Abbreviations: IC50¼inhibitory concentration 50%; monoHER¼7-mono-O-
(b-hydroxyethyl)-rutoside,
aData are expressed as mean±s.d. *Pp0.05.
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sdrug resistance (Meister, 1991; Estrela et al, 2006). This can be
achieved by inhibitors of GSH synthesis such as BSO, a selective
and irreversible inhibitor of g-glutamylcysteine synthase, the rate
limiting enzyme of GSH synthesis (Han and Park, 2009). As also
shown by our results, BSO efficiently enhances the effect of several
chemotherapeutic drugs including doxorubicin (Vanhoefer et al,
1996). In addition, some flavonoids can also deplete GSH levels in
cancer cells, thereby sensitising these cancer cells to chemotherapy
(Kachadourian and Day, 2006; Kachadourian et al, 2007; Ramos
and Aller, 2008). Because monoHER is able to form a
GSH–monoHER adduct that might deplete cells from GSH (Jacobs
et al, 2009), we examined whether monoHER can deplete GSH in
WLS-160 cells. However, in contrast to BSO, monoHER did not
significantly change GSH levels in WLS-160 cells, suggesting that
the growth-inhibitory effect of monoHER is not mediated via GSH
depletion.
Another crucial factor involved in drug resistance is NF-kB, an
inducible and ubiquitously expressed transcription factor that
regulates cell survival, inflammation and differentiation (Karin,
2006). Many chemotherapeutic agents induce the activity of
NF-kB, which causes drug resistance in cancer cells (Sarkar and
Li, 2008). Because doxorubicin rapidly induced NF-kB activity in
WLS-160 cells within 6h, inhibition of NF-kB was expected to
enhance the antitumour activity of doxorubicin, similar to several
in vitro and preclinical in vivo studies in which the regulation of
NF-kB enhanced the efficacy of chemotherapy (Bava et al, 2005;
Li et al, 2005; Nakanishi and Toi, 2005; Sung et al, 2007). Our
results show that monoHER prevented the NF-kB induction by
doxorubicin in WLS-160 cells, suggesting that downregulation of
NF-kB activation by monoHER may be responsible for the
sensitisation of these cancer cells to doxorubicin. Figure 2 further
illustrates this mechanism.
In conclusion, monoHER enhanced the cytotoxicity of
doxorubicin in the human liposarcoma cell line WLS-160.
This potentiation was not mediated by GSH depletion, but
monoHER reduced doxorubicin-induced NF-kB activation, there-
by sensitising tumour cells to apoptosis. Thus, the high response
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Figure 1 Effect of the semi-synthetic flavonoid monoHER on the cytotoxic effects of doxorubicin in the liposarcoma cell line WLS-160. (A) MonoHER
pretreatment (50mM; 1h) significantly enhances the cell growth inhibition induced by doxorubicin (0.001–0.1mM; 72h) (mean±s.d. *Pp0.05 compared
with doxorubicin treatment). (B) MonoHER pretreatment (50mM; 1h) significantly enhances the apoptosis induced by doxorubicin (10mM; 6h) (mean±s.d.
*Pp0.05 compared with doxorubicin treatment). Relative light units (RLUs); doxorubicin (DOX). (C) MonoHER treatment (50mM; 1, 6 and 24h) has no
effect on the intracellular GSH concentration, whereas BSO (50mM; 1, 6 and 24h) reduces GSH levels in a time-dependent manner (mean±s.d. *Pp0.05
compared with control). (D) MonoHER pretreatment (50mM; 1h) significantly prevents doxorubicin-induced (10mM; 6h) NF-kB activation (mean±s.d.
*Pp0.05 compared with doxorubicin treatment).
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Figure 2 Suggested pathway illustrating the influence of monoHER on
doxorubicin cytotoxicity in WLS-160 cells. Under resting conditions, NF-kB
is maintained in an inactive state in the cytoplasm via interaction with the
inhibitory protein, IkB. Doxorubicin can activate the NF-kB pathway, which
involves the phosphorylation, ubiquitination and proteasomal degradation
of IkB. Nuclear factor-kB is then free to translocate to the nucleus where it
facilitates the transcription of, for example, antiapoptotic genes, resulting in
less tumour cell killing and the development of drug resistance. MonoHER
is able to reduce this doxorubicin-induced NF-kB activation, thereby
sensitising WLS-160 cells to doxorubicin-induced apoptosis.
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srate in the clinical phase II study may be mediated by reduction of
doxorubicin-induced NF-kB activation. For certain STS patients,
monoHER might improve chemotherapy and even decrease
systemic toxicity. Moreover, monoHER might also be valuable
for the treatment of other tumours that have developed
chemoresistance through NF-kB activation. However, future
studies are needed to further elucidate the value of adding
monoHER to the chemotherapeutic treatment with doxorubicin.
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